Prelude Capital Management, LLC Mei Pharma, Inc. Transaction History

Prelude Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $17,010 - $86,310	-31,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.52 - $2.99 $21,420 - $25,415	8,500 Added 36.96%	31,500 $87,000
Q4 2020 Feb 16, 2021	SELL	$2.6 - $3.32 $75,293 - $96,143	-28,959 Reduced 55.73%	23,000 $61,000
Q3 2020 Nov 16, 2020	BUY	$2.46 - $4.27 $61,165 - $106,169	24,864 Added 91.77%	51,959 $162,000
Q2 2020 Aug 14, 2020	BUY	$1.45 - $4.3 $39,287 - $116,508	27,095 New	27,095 $112,000
Q4 2017 Feb 14, 2018	SELL	$1.91 - $2.83 $29,032 - $43,016	-15,200 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.44 - $2.91 $37,088 - $44,232	15,200	15,200 $41,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $362M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.